Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Ipca Laboratories Limited, a pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, CIS, and Australasia. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company also provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, hematology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. It also exports its products worldwide. The company was incorporated in 1949 and is based in Mumbai, India.

Revenue projections:

Revenue projections for IPCALAB
Revenue projections for IPCALAB

Investors are expected to be cautious with IPCALAB, as its revenues are projected to fall compared to last year. A decline in revenue often results in a negative impact on profitability, prompting concerns about the company's financial stability and making investors more conservative in their approach.

Financial Ratios:

currentRatio 2.76400
forwardPE 24.64429
debtToEquity 8.49200
earningsGrowth 3.41600
revenueGrowth 0.06200
grossMargins 0.70738
operatingMargins 0.15773
trailingEps 44.99000
forwardEps 65.73125

IPCALAB's current ratio of 2.764, indicating that the company can meet its short-term debt obligations with ease. This high liquidity level is a positive sign, as IPCALAB has enough cash and current assets to handle its immediate liabilities comfortably.
Ipca Laboratories Limited's Forward PE is at a healthy level, meaning the stock price is aligned favorably with earnings. This suggests that the stock isn't overpriced, providing room for growth and making it an appealing option for investors looking to capitalize on potential future gains.
IPCALAB's forward EPS exceeding its trailing EPS reflects expectations of increased profitability for the current year. This suggests that the company is projected to achieve higher earnings than in the previous financial year, signaling positive growth and improved financial health.

Price projections:

Price projections for IPCALAB
Price projections for IPCALAB

The price of IPCALAB has often been situated close to the lower end of projections. This consistent trend may signal difficulties for the company in achieving investor expectations for future performance.

Insider Transactions:

Insider Transactions for IPCALAB
Insider Transactions for IPCALAB


2 sales of IPCALAB stock were made, with market price at 1456.75 per share.No sell transactions took place in the period under consideration.An increase in buying activity relative to selling at IPCALAB's current price might suggest a favorable sentiment among investors. This trend could be interpreted as a sign that the stock has a positive outlook in the near term.

Recommendation changes over time:

Recommendations trend for IPCALAB
Recommendations trend for IPCALAB


Analysts have been favoring IPCALAB with a buy bias recently, signaling a promising investment opportunity. This optimistic outlook may attract more investors, positioning IPCALAB as a desirable option for those seeking to invest their money in a stable, profitable company with strong growth potential.